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LETTERS
The eosinophilic pleural and pul-
monary response may be elicited by
the larvae of helminths carried
hematogenously into lungs and pleura
in an aberrant fashion (3). The last
point we stress is that, as shown by
Moore et al. (1), patients returning
from disease-endemic areas, mainly
Southeast Asia and Central and South
America, should be tested systemati-
cally for gnathostomiasis. Although
some patients show a typical cuta-
neous form of gnathostomiasis associ-
ated with eosinophilia (6,7), most
atypical forms are probably under-
diagnosed, and severe neurologic
involvement may occur if treatment is
not given (1). However, until recently
specific serologic tests for gnathosto-
miasis were available only in Asia,
mainly in Thailand and Japan. Some
laboratories in Europe currently pro-
vide testing for gnathostomiasis,
which would be a valuable aid in eval-
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To the Editor: This letter is writ-
ten in response to the article titled
“Co-trimoxazole-sensitive, methi-
cillin-resistant Staphylococcus aureus,
Israel, 1988–1997” (1). We found the
authors’ findings most interesting. As
the authors pointed out, methicillin-
resistant  Staphylococcus aureus
(MRSA) infections have become a
major problem worldwide. The prob-
lem is not restricted to industrialized
countries. The last decade has seen an
alarming increase in MRSAinfections
in Pakistani hospitals (2). Pakistan’s
Armed Forces Institute of Pathology
provides laboratory services to a
1,500-bed tertiary-care hospital in
Rawalpindi and is the main reference
laboratory in northern Pakistan.
According to our computerized data-
base, the frequency of MRSA among
all nosocomial isolates of S. aureus
increased from 39% (212/543) in
1996 to 51% (516/1,018) in 2003 (p <
0.0001). Most of the isolates were
obtained from pus and pus swab spec-
imens (153 in 1996 and 394 in 2003),
while the rest were obtained from
blood (20 in 1996 and 37 in 2003),
intravenous catheter tips and surgical
drainage tubes (14 in 1996 and 31 in
2003), various body fluids (9 in 1996
and 19 in 2003), respiratory secretions
(8 in 1996 and 18 in 2003), tissue (4
in 1996, 9 in 2003), throat swabs (2 in
1996, 6 in 2003), and urine (2 in 1996,
5 in 2003).
During the last 7 years, resistance
in MRSA isolates has steadily
increased to most of the antimicrobial
drugs such as gentamicin (69% in
1996 and 88% in 2003), ciprofloxacin
(87% in 1996 and 94% in 2003), clin-
damycin (60% in 1996 and 70% in
2003), and rifampicin (20% in 1996
and 60% in 2003). However, resist-
ance to co-trimoxazole and doxycy-
cline has decreased. In 1996, 15%
(32/212) of our MRSA isolates were
susceptible to co-trimoxazole, where-
as in the first 9 months of 2003, 43%
(222/516) of the isolates were suscep-
tible (p < 0.0001). Similarly, suscepti-
bility to doxycycline increased from
34% in 1996 to 49% in 2003 (p =
0.0005). Antimicrobial drug suscepti-
bility of the isolates was tested by the
modified Kirby-Bauer technique and
results were interpreted according to
the National Committee for Clinical
Laboratory Standards criteria (3).
Methicillin resistance was tested by
using 1 µg oxacillin disks (Oxoid,
Basingstoke, Hampshire, UK) on
Mueller-Hinton agar containing 4%
sodium chloride. Plates were incubat-
ed at 35°C for 24 hours.
We agree with Bishara et al. (1)
that the increase in susceptibility is
likely due to decreased use of these
antimicrobial drugs for staphylococ-
cal infections in clinical practice. The
use of co-trimoxazole in our hospital
decreased from 48 daily doses per
1,000 hospital days in 1996 to 35
daily doses in 2003, while use of
doxycycline decreased from 12 daily
doses per 1,000 hospital days in 1996
to 9 daily doses in 2003 (4). These
antimicrobial drugs offer an inexpen-
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sive alternative to glycopeptides for
the treatment of MRSA infections.
Data from the United States and
Europe have shown that vancomycin-
intermediate  S. aureus isolates also
remain susceptible to some of the con-
ventional antimicrobial drugs, includ-
ing co-trimoxazole (5). If their effica-
cy in vivo is validated by clinical tri-
als, use of these conventional drugs
would not only reduce the load on
overstretched health care budgets but
reduce the use of vancomycin, there-
fore decreasing the risk of isolates
continuing to develop vancomycin
resistance.
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To the Editor: Lyme borreliosis is
the most common tickborne human
disease in the Northern Hemisphere.
The incidence of the disease is not the
same throughout Europe; in southern
Europe, the incidence ranges from
43% in Croatia to 1.1% in Greece.
Suspected borreliosis cases have been
reported in Greece, none were con-
firmed.  Ixodes ricinus, the principal
tick vector of Borrelia burgdorferi in
Europe, is found in northern Greece.
A low prevalence of B. burgdorferi
antibodies was found in healthy per-
sons in Greece (1,2); a frequency of
7.3% was found in arthritis patients
(1), while a frequency of 16.9% was
found in patients with neurologic dis-
orders (E. Diza, unpub. data). 
Polymerase chain reaction (PCR)
has been used to detect B. burgdorferi
DNA in humans and to determine
genospecies (3). Isolates found in the
United States have constituted a
homogeneous group. In Europe, five
different genospecies from the origi-
nal  B. burgdorferi, now called
burgdorferi sensu lato complex, have
been described: B. burgdorferi sensu
stricto,  B. garinii,  B. afzelii, B.
valaisiana, and B. lusitaniae. Patho-
genicity for humans remains
uncertain for B. valaisiana and  B.
lusitaniae (4).
Neuroborreliosis, the most serious
manifestation of disseminated Lyme
disease, has become the most fre-
quently recognized arthropodborne
infection of the nervous system in the
United States and Europe. B. garinii,
B. afzelii, and B. burgdorferi sensu
stricto are confirmed causes of neu-
roborreliosis (5); however, B.
valaisiana has not been isolated from
cerebrspinal fluid (CSF) until this
report.
We report the genetic detection of
B. valaisiana in the CSF of a 61-year-
old man with a history of spastic para-
paresis, which is strong clinical evi-
dence of advanced neuroborreliosis.
Symptoms, mainly difficulty in walk-
ing, began approximately 10 years
earlier, with a slow progressive course
of neuroborreliosis. His medical his-
tory showed an unidentified sexually
transmitted disease in 1982, an unde-
fined episode of arthritis in the lower
limbs in 1990, and a nonspecific rash
in the genitals in 1995. The patient
lived in South Africa from 1961 to
1997 and visited Thassos Island in
northern Greece every year. The neu-
rologic examination demonstrated an
intense pyramidal spasticity in the
lower limbs and moderate weakness
(Medical Research Council grade 3)
of the proximal muscles. Serial mag-
netic resonance imaging (MRI) of the
brain showed small hyperintensities
in the periventricular area on T2-
weighted images; MRI of the spinal
cord showed no abnormalities.
Multiple sclerosis, B12 deficiency,
human T-cell lymphotrophic virus-1
infection, structural inflammatory
lesions of the spinal cord, motor neu-
ron disease, and hereditary spastic
paraplegia have been excluded. The
patient was treated occasionally with
intravenous penicillin G, as well as
with corticosteroids, but no clinical
improvement was achieved. Venereal
disease reaction level was negative
and all tests for syphilis in CSF were
negative. 
DNAwas extracted from CSF, and
a region of the chromosomal flagellin
gene of B. burgdorferi was amplified
by nested PCR (3). B. afzelii (VS461)
DNA was used as a positive control.
All precautions were taken to avoid
contamination. The amplified PCR
product was sequenced, and the
sequence (Th1) was deposited in
GenBank with the accession no.
AY270021. Phylogenetic analysis
showed that strain Th1 was clustering
with strains belonging to B.
valaisiana  genomic group.
Specifically, a nucleotide difference
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